Cellestis Ltd. develops, manufactures and markets medical diagnostic products. It develops and markets QuantiFERON technology products for medical diagnosis and scientific research. The QuantiFERON technology is a patented whole blood method for detecting cell mediated immune responses of T cell lymphocytes using whole blood samples. Its product portfolio includes QuantiFERON-CMI kit, an in vitro laboratory test for the measurement of cell mediated immune responses in humans using whole blood, QuantiFERON-TB Gold, an in vitro diagnostic test for the detection of mycobacterium tuberculosis infection. The company was founded in 2000 and is headquartered in Chadstone, Australia.